HI caldeerster,

Todd Scherer reply from MJFF:

I can’t add much on Il-1 but related to TNF-alpha, the biggest issue is related to potential peripheral toxicity of compounds and this has been a roadblock for development. There is some effort to develop drugs targeting these pathways, however. We have funded a group led by Malu Tansey to develop TNF alpha drugs that specifically target the brain with minimal side effects. There are also a few biotechs working in the area as well.

I do think it is still controversial as to the exact role of inflammation in PD (whether inflammation is truly involved in PD onset, for example, or is secondary part of the neurodegenerative process).

Todd